Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.
2.

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ.

J Clin Psychiatry. 2001 Mar;62(3):199-203.

PMID:
11305707
3.

Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.

Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB.

Am J Psychiatry. 2005 Mar;162(3):621-4.

PMID:
15741486
4.

Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder.

Silva H, Iturra P, Solari A, Villarroel J, Jerez S, Vielma W, Montes C, Pumarino L, Roa N.

Actas Esp Psiquiatr. 2007 Nov-Dec;35(6):387-92.

PMID:
17597424
5.
6.

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.

J Clin Psychiatry. 2003 Jun;64(6):640-7.

PMID:
12823077
7.

Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics?

Abraham PF, Calabrese JR.

J Affect Disord. 2008 Nov;111(1):21-30. doi: 10.1016/j.jad.2008.01.024. Review.

PMID:
18304647
8.

Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

Goodman WK, Kozak MJ, Liebowitz M, White KL.

Int Clin Psychopharmacol. 1996 Mar;11(1):21-9.

PMID:
8732310
9.

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response.

Pearlstein T, Spurell E, Hohlstein LA, Gurney V, Read J, Fuchs C, Keller MB.

Arch Womens Ment Health. 2003 Apr;6(2):147-51.

PMID:
12720065
10.

Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.

Asnis GM, Hameedi FA, Goddard AW, Potkin SG, Black D, Jameel M, Desagani K, Woods SW.

Psychiatry Res. 2001 Aug 5;103(1):1-14.

PMID:
11472786
11.

Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, Rother WK, Loew TH.

J Clin Psychiatry. 2004 Nov;65(11):1515-9.

PMID:
15554765
12.

A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.

Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C.

Biol Psychiatry. 2000 May 1;47(9):813-7.

PMID:
10812040
13.

Efficacy and tolerability of pharmacotherapies for borderline personality disorder.

Bellino S, Paradiso E, Bogetto F.

CNS Drugs. 2008;22(8):671-92. Review.

PMID:
18601305
14.
15.

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.

Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT.

J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):222-9.

PMID:
11211371
16.

Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.

Nair NP, Bakish D, Saxena B, Amin M, Schwartz G, West TE.

Anxiety. 1996;2(4):192-8.

PMID:
9160622
17.

A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.

Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M.

J Clin Psychopharmacol. 2012 Oct;32(5):593-601. doi: 10.1097/JCP.0b013e3182664cfc.

PMID:
22926591
18.

[Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder].

Fukuda T, Sugie H, Ito M, Sugie Y.

No To Hattatsu. 2001 Jul;33(4):314-8. Japanese.

PMID:
11494573
19.

Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.

Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH.

Int Clin Psychopharmacol. 2010 Jul;25(4):189-98. doi: 10.1097/YIC.0b013e328330adb2.

PMID:
20531012
20.

Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.

Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S.

Int Clin Psychopharmacol. 2014 Nov;29(6):344-50. doi: 10.1097/YIC.0000000000000043.

PMID:
24850229
Items per page

Supplemental Content

Support Center